Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 9/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916278 | 0.85 | POLB (0.70) | POLBGAAMAPTADAMTS5 | |
| SCHEMBL10112748 | 0.83 | POLB (0.68) | POLBGAAMAPTKMT2ANPSR1 | |
| SCHEMBL4023021 | 0.83 | POLB (0.64) | POLBGAAMAPTPLK1 | |
| SCHEMBL10131638 | 0.83 | POLB (0.68) | POLBGAAMAPTKMT2ANPSR1 | |
| SCHEMBL3635448 | 0.83 | POLB (0.73) | POLBGAAMAPTKMT2AKDM4E | |
| SCHEMBL6646189 | 0.83 | POLB (0.68) | POLBGAAMAPTNPSR1KDM4E | |
| SCHEMBL12262808 | 0.83 | POLB (0.68) | POLBGAAMAPTKMT2AKDM4E | |
| SCHEMBL31155136 | 0.83 | MAPT (0.75) | POLBGAAMAPTKMT2AKDM4E | |
| SCHEMBL7572017 | 0.82 | POLB (0.55) | POLBGAAMAPTKMT2ANPSR1 | |
| SCHEMBL7093309 | 0.82 | POLB (0.55) | POLBGAAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605621-B | Hydrogen bond donor-boron organic catalyst and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-01-30 | — | — | CN | disclosed |
| CN-114605621-A | Hydrogen bond donor-boron organic catalyst and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2022-06-10 | — | — | CN | disclosed |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF (US) | 2019-01-31 | — | — | US | disclosed |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2776445-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
| EP-1197485-B1 | Cyclobuten-dione derivatives for use in the treatment of artherosclerosis | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | SMITHKLINE BEECHAM CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-6696469-B2 | FOR TREATMENT OF DISEASES OR PATHOLOGICAL CONDITIONS IN WHICH ENDOTHELIAL DYSFUNCTION IS KNOWN; ATHEROSCLEROSIS, DYSLIPIDAEMIA, DIABETES | LES LABORATOIRES SERVIER (FR) | 2004-02-24 | — | — | US | disclosed |
| EP-1383488-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020065419-A1 | Cyclobutenedione compounds | LES LABORATOIRES SERVIER (FR) | 2002-05-30 | — | — | US | disclosed |
| EP-1197485-A1 | Cyclobuten-dione derivatives for use in the treatment of artherosclerosis | Les Laboratoires Servier (FR) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | COMT, BPHL, PNMT | POLB 642/4885GAA 1129/4885MAPT 2532/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | POLB 296/4885GAA 1398/4885MAPT 2357/4885 |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | POLB 1117/4885GAA 2580/4885MAPT 3670/4885 |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | POLB 1117/4885GAA 2580/4885MAPT 3670/4885 |
| US-20020065419-A1 | Cyclobutenedione compounds | NR3C2, NR5A1, CYP11B1 | POLB 630/4885GAA 4303/4885MAPT 3977/4885 |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | POLB 1466/4885GAA 3094/4885MAPT 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.